Mitochondrial complex 1 inhibition increases 4-Repeat isoform tau by SRSF2 upregulation

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Bruch, Julius ^a,b   Xu, Hong ^a,b   De Andrade, Anderson ^a   Höglinger, Günter ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ANNONACIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SERINE ARGININE RICH PROTEIN; SRSF2 PROTEIN; TAU PROTEIN; TRA2B PROTEIN; UNCLASSIFIED DRUG; FURAN DERIVATIVE; LACTONE; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; RNA ISOFORM; SRSF2 PROTEIN, HUMAN;

AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BRAIN NERVE CELL; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCUS CERULEUS; MALE; OXIDATIVE STRESS; PROGRESSIVE SUPRANUCLEAR PALSY; UPREGULATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN DOMAIN;

ALTERNATIVE SPLICING; ELECTRON TRANSPORT COMPLEX I; FEMALE; FURANS; GENE EXPRESSION REGULATION; HUMANS; LACTONES; NUCLEAR PROTEINS; OXIDATIVE STRESS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RIBONUCLEOPROTEINS; RNA ISOFORMS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; UP-REGULATION;

EID: 84913553259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113070     Document Type: Article

References (28)

1. Williams DR (2006) Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36: 652-660
2. Liu F, Gong CX (2008) Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 3: 8
3. Chen S, Townsend K, Goldberg TE, Davies P, Conejero-Goldberg C (2010) MAPT isoforms: differential transcriptional profiles related to 3R and 4R splice variants. J Alzheimers Dis 22: 1313-1329
4. Buee L, Delacourte A (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 9: 681-693
5. Zhou J, Yu Q, Zou T (2008) Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC Neurosci 9 Suppl 2: S10
6. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, et al. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95: 7737-7741
7. Avale ME, Rodriguez-Martin T, Gallo JM (2013) Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing. Hum Mol Genet 22: 2603-2611
8. Will CL, Luhrmann R (2011) Spliceosome structure and function. Cold Spring Harb Perspect Biol 3
9. Pilch B, Allemand E, Facompre M, Bailly C, Riou JF, et al. (2001) Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 61: 6876-6884
10. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD (2009) Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 23: 482-495
11. Swerdlow RH, Golbe LI, Parks JK, Cassarino DS, Binder DR, et al. (2000) Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 75: 1681-1684
12. Lenaz G, Baracca A, Fato R, Genova ML, Solaini G (2006) Mitochondrial Complex I: structure, function, and implications in neurodegeneration. Ital J Biochem 55: 232-253
13. Stamelou M, de Silva R, Arias-Carrion O, Boura E, Hollerhage M, et al. (2010) Rational therapeutic approaches to progressive supranuclear palsy. Brain 133: 1578-1590
14. Albers DS, Swerdlow RH, Manfredi G, Gajewski C, Yang L, et al. (2001) Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 168: 196-198
15. Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, et al. (2009) In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab 29: 861-870
16. Lannuzel A, Michel PP, Hoglinger GU, Champy P, Jousset A, et al. (2003) The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 121: 287-296
17. Lannuzel A, Hoglinger GU, Verhaeghe S, Gire L, Belson S, et al. (2007) Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 130: 816-827
18. Escobar-Khondiker M, Hollerhage M, Muriel MP, Champy P, Bach A, et al. (2007) Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 27: 7827-7837
19. Yamada ES, Respondek G, Mussner S, de Andrade A, Hollerhage M, et al. (2014) Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol 253C: 113-125
20. Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, et al. (2005) Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 25: 6329-6342
21. Scholz D, Poltl D, Genewsky A, Weng M, Waldmann T, et al. (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119: 957-971
22. Silver IA, Erecinska M (1994) Extracellular glucose concentration in mammalian brain: continuous monitoring of changes during increased neuronal activity and upon limitation in oxygen supply in normo-, hypo-, and hyperglycemic animals. J Neurosci 14: 5068-5076
23. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50: 55-66
24. Schapira AH (2010) Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol 224: 331-335
25. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, et al. (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95: 930-939
26. Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA (1999) Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46: 325-332
27. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, et al. (2011) Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 30: 510-523
28. Edmond V, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2011) SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle 10: 1968-1977.